Chiltern rondt overname Theorem Clinical Research af
LONDeN & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, een wereldwijde leider op het gebied van uitbesteed onderzoek, heeft de overname van Theorem Clinical Research afgerond, waarmee het zijn positie als de grootste middelgrote leverancier van uitgebreide, maar flexibele en toegankelijke klinische ontwikkelservice versterkt.
Chiltern omvat nu 3700 mensen in 47 landen, waarmee de voetafdruk van Chiltern in Europa, Noord-Amerika en Oost-Azië wordt vergoot. De acquisitie versterkt het aanbod van Chiltern op het gebied van oncologie, biofarmacie en inkoop, verbreedt de therapeutische expertise en zorgt voor nieuwe mogelijkheden op het gebied van medische apparatuur en diagnostiek, klinische analyses en klinische benodigdheden.
“Door Chiltern en Theorem samen te brengen, hebben we een unieke, middelgrote onderzoekspartner gecreëerd die zich richt op het bieden van van uitzonderlijke wetenschappelijke expertise en persoonlijke service”, zegt Dr. Jim Esinhart, CEO bij Chiltern.
Chiltern Finalizes Acquisition of Theorem Clinical Research
LONDON & WILMINGTON, N.C.–(BUSINESS WIRE)– Chiltern, a leading global contract research organization (CRO), has completed its acquisition of Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive, yet flexible and responsive, clinical development services.
Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern’s footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern’s Oncology,Biopharma and Source offerings, broadens its therapeutic expertise and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.
“By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service,” said Dr. Jim Esinhart, Chiltern CEO. “Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials.”
“The acquisition of Theorem marks an important milestone for Chiltern,” said Nick Thornton, Chiltern chairman. “We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce that Dr. John Potthoff, Theorem’s president and CEO, has joined our board as a non-executive director.”
About Chiltern:
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 3,700 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. VisitChiltern.com to learn more about responsive solutions that are Designed Around You ®.
Chiltern was advised by Jefferies LLC, Hughes Hubbard & Reed LLP, Simmons & Simmons LLP and Deloitte LLP, London. Theorem was advised by Robert W. Baird & Co. and Goodwin Procter LLP.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150914005595/en/
Contacts
SCORR Marketing
Lea Studer, 308-237-5567
lea@scorrmarketing.com
Check out our twitter: @NewsNovumpr